Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Cash & Equivalents: 2023-2025

  • Zhengye Biotechnology Holding's Cash & Equivalents was N/A to $6.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $6.3 million, marking a year-over-year change of. This contributed to the annual value of $2.5 million for FY2024, which is 19.51% up from last year.
  • Latest data reveals that Zhengye Biotechnology Holding reported Cash & Equivalents of $6.3 million as of Q2 2025, which was up 147.37% from $2.5 million recorded in Q4 2024.
  • Zhengye Biotechnology Holding's Cash & Equivalents' 5-year high stood at $6.3 million during Q2 2025, with a 5-year trough of $2.1 million in Q4 2023.
  • In the last 3 years, Zhengye Biotechnology Holding's Cash & Equivalents had a median value of $2.5 million in 2024 and averaged $3.6 million.
  • Data for Zhengye Biotechnology Holding's Cash & Equivalents shows a peak YoY rose of 21.76% (in 2024) over the last 5 years.
  • Zhengye Biotechnology Holding's Cash & Equivalents (Quarterly) stood at $2.1 million in 2023, then rose by 21.76% to $2.5 million in 2024, then reached $6.3 million in 2025.
  • Its last three reported values are $6.3 million in Q2 2025, $2.5 million for Q4 2024, and $2.1 million during Q4 2023.